Shilajit, a Himalayan substance used in Ayurvedic medicine, offers antioxidant and anti-inflammatory benefits. Studies suggest it boosts testosterone, ...

Keep reading as we share a list of people that can benefit from shilajit. 10 People who need to add shilajit to their routine 1. Men with low testosterone levels ...

As Biogen aims to grow sales of postpartum depression drug Zurzuvae, it’s turning to well-funded telehealth company Talkiatry to boost awareness of and care for the often overlooked condition.

Is Shilajit legit? The tarlike resin found in the Himalayas has been used in ayurvedic medicine for centuries and is lately making the rounds on TikTok. Known as "The Healer of All Weaknesses ...

Biogen is placing a $1.15 billion bet on Chris Viehbacher’s diversification vision. The upfront payment has secured Biogen a deal to buy Human Immunology Biosciences (HI-Bio), a biotech that is ...

Biogen’s CEO may have been celebrating “turning a corner” last month, but it looks like the drugmaker’s early-stage pipeline hasn’t gotten the message yet. | Biogen’s CEO may have been ...

More than two years after Aduhelm's controversial and ill-fated FDA accelerated approval, Bi | Biogen is discontinuing its first Alzheimer's disease therapy, Aduhelm, after walking a rocky path ...

Biogen will give up ownership and halt sales of Aduhuelm, an Alzheimer's disease drug that met skepticism and scrutiny following its 2021 approval.

Shilajit has been used for thousands of years by holistic medical systems. Here’s what to know about shilajit’s potential health benefits, uses and safe dosage.

The cuts are part of a 1,000-person downsizing round Biogen unveiled late July to save $700 million in annual costs. Boston Business Journal first reported Thursday’s initiation of layoffs.

Texas-based Reata Pharmaceuticals, which earlier this year got the first federal approval to treat degenerative disease Friedreich's ataxia, is set to be acquired by Biogen in a deal valued at $7. ...

Samantha Budd Haeberlein, the Biogen senior executive who supervised the development and controversial approval of the Alzheimer’s treatment Aduhelm, has left the company, STAT has learned.